A Phase 1b/2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Avelumab (Primary) ; PF 4518600 (Primary) ; Utomilumab (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms JAVELIN Medley
- Sponsors Pfizer
- 30 Jun 2017 Planned number of patients changed from 549 to 671.
- 06 Jun 2017 Planned End Date changed from 1 Dec 2019 to 1 Feb 2020.
- 22 May 2017 Planned End Date changed from 21 May 2020 to 1 Dec 2019.